Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 variant omicron BA.5 mRNA vaccine
- Development stage
- Unknown
- Lead developer
- AIM Vaccine Co.
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SARS-CoV-2 variant omicron BA.5 mRNA vaccine refers to a category of mRNA-based vaccines engineered to target the spike protein of the SARS-CoV-2 Omicron BA.5 subvariant. A specific example is **LVRNA012**, developed by AIM Vaccine Co., Ltd. in collaboration with Liverna Therapeutics Inc. This vaccine candidate encodes the spike antigen of the BA.5 variant and is formulated for intramuscular administration. In clinical studies, LVRNA012 has been evaluated as a heterologous booster in adults who previously received inactivated COVID-19 vaccines. Results from a Phase 3 clinical trial (NCT05745545) in China demonstrated a vaccine efficacy of 51.9% against symptomatic COVID-19 and significant induction of neutralizing antibodies against various Omicron lineages, including XBB.1.5.
- Other names
- SARS-CoV-2 variant omicron BA.5 mRNA vaccineSARS-CoV2 variant omicron BA.5 mRNA vaccineSARS-CoV 2 variant omicron BA.5 mRNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS-CoV-2 variant omicron BA.5 mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 variant omicron BA.5 mRNA vaccine.